Mittal Abhinav, Forte Michael, Leonard Rachel, Sangani Rahul, Sharma Sunil
Pulmonary, Critical Care & Sleep Medicine, West Virginia University, Morgantown, USA.
Internal Medicine, Section of Pulmonary, Critical Care & Sleep Medicine, West Virginia University, Morgantown, USA.
Cureus. 2020 Apr 27;12(4):e7849. doi: 10.7759/cureus.7849.
Coronavirus disease 2019 (COVID-19) is a respiratory illness caused by the highly infectious novel SARS-CoV-2 coronavirus spread by droplet transmission. Consequently, the use of respiratory devices that may potentially promote aerosolization like non-invasive positive pressure ventilation (NIPPV) for diseases such as obstructive sleep apnea (OSA), advanced chronic obstructive lung disease, pulmonary hypertension (PH), and neuromuscular respiratory disease has been called into question. We present a case of a patient with history of OSA and PH convalescing from refractory acute respiratory distress syndrome (ARDS) secondary to COVID-19 who was successfully extubated to average volume-assured pressure support (AVAPS). A 74-year-old male with medical history notable for OSA on NIPPV, PH, and hypertension presented with respiratory failure secondary to COVID-19 confirmed on polymerase chain reaction (PCR) test. His respiratory status worsened leading to ARDS requiring intubation. He was initially extubated to high flow nasal cannula (HFNC) due to hospital policy to avoid NIPPV due to concerns of viral dissemination. He did not tolerate HFNC and required re-intubation for prolonged period. He was then medically optimized for a second attempt and extubated two days later to AVAPS with an anti-viral filter and negative pressure room with a goal of optimizing his critical illness myopathy and pre-existing OSA and PH. He tolerated extubation well, and over the next five days was weaned from alternating AVAPS/HFNC to eventually requiring two liters nasal cannula in the day and AVAPS mode at night. This case highlights a potential therapeutic option for patients with severe respiratory failure secondary to COVID-19. This patient's pre-existing comorbidities of OSA and PH markedly increased his risk for extubation failure on HFNC. The use of AVAPS after his second extubation attempt helped ensure ventilation and oxygenation non-invasively. COVID-19 can lead to prolonged dependence on mechanical ventilation. This pandemic has the potential to create medical resource scarcities, especially in rural areas where ventilators and trained personnel are already in short supply. By using AVAPS mode, this patient was able to rehabilitate his myopathy and participate in intermittent weaning of HFNC to ultimately simple nasal cannula. AVAPS is useful tool to facilitate extubation, as it allows non-invasive support of respiratory dynamics, particularly in those with co-morbidities such as OSA and PH. Further, larger scale studies are needed to determine its exact role during the COVID-19 pandemic.
2019冠状病毒病(COVID-19)是一种由具有高度传染性的新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)通过飞沫传播引起的呼吸道疾病。因此,对于诸如阻塞性睡眠呼吸暂停(OSA)、晚期慢性阻塞性肺疾病、肺动脉高压(PH)和神经肌肉性呼吸疾病等疾病,使用可能会促进气溶胶形成的呼吸设备,如无创正压通气(NIPPV),已受到质疑。我们报告一例有OSA和PH病史的患者,该患者因COVID-19继发难治性急性呼吸窘迫综合征(ARDS)正在康复,成功撤机至平均容量保证压力支持(AVAPS)模式。一名74岁男性,有因OSA使用NIPPV、PH和高血压病史,因聚合酶链反应(PCR)检测确诊为COVID-19继发呼吸衰竭。他的呼吸状况恶化,导致ARDS需要插管。由于医院政策担心病毒传播而避免使用NIPPV,他最初撤机至高流量鼻导管(HFNC)。他不能耐受HFNC,需要长时间再次插管。然后对他进行了医学优化以进行第二次尝试,两天后撤机至带有抗病毒过滤器的AVAPS模式,并置于负压病房,目的是改善他的危重病性肌病以及原有的OSA和PH。他对撤机耐受良好,在接下来的五天里,从交替使用AVAPS/HFNC逐渐撤机,最终白天需要两升鼻导管吸氧,夜间使用AVAPS模式。该病例突出了COVID-19继发严重呼吸衰竭患者的一种潜在治疗选择。该患者原有的OSA和PH合并症显著增加了他在HFNC上撤机失败的风险。第二次撤机尝试后使用AVAPS有助于确保无创通气和氧合。COVID-19可导致对机械通气的长期依赖。这场大流行有可能造成医疗资源短缺,特别是在农村地区,那里呼吸机和训练有素的人员已经短缺。通过使用AVAPS模式,该患者能够恢复其肌病,并参与HFNC的间歇性撤机,最终过渡到单纯鼻导管吸氧。AVAPS是促进撤机的有用工具,因为它允许对呼吸动力学进行无创支持,特别是对于那些有OSA和PH等合并症的患者。此外,需要更大规模的研究来确定其在COVID-19大流行期间的确切作用。